摘要
目的:系统评价贝那普利对比卡托普利治疗原发性高血压的疗效与安全性,以为临床治疗提供循证参考。方法:计算机检索Cochrane图书馆、Pub Med、EMBase、中国期刊全文数据库、中文科技期刊全文数据库和万方数据库,收集贝那普利(试验组)对比卡托普利(对照组)治疗原发性高血压的随机对照试验(RCT),提取资料并评价质量后,采用Rev Man 5.0统计软件进行Meta分析。结果:共纳入7项RCT,合计405例患者。Meta分析结果显示,试验组患者收缩压[MD=-2.06,95%CI(-3.75,-0.38),P=0.02]、舒张压[MD=-3.10,95%CI(-5.19,-1.01),P=0.004]均显著低于对照组;但两组患者降压有效率[OR=1.63,95%CI(0.69,3.83),P=0.26]和不良反应发生率[OR=0.81,95%CI(0.46 1.41),P=0.45]比较差异均无统计学意义。结论:贝那普利较卡托普利能更显著地降低原发性高血压患者血压。受纳入研究方法学质量限制,该结论有待高质量、大样本的RCT进一步证实。
OBJECTIVE：To systematically analyze the efficacy and safety of benazepril vs. captopril in the treatment of primary hypertension and provide evidence-based reference for the clinical treatment. METHODS：Cochrane Library,Pub Med,EMBase,CJFD,VIP database and Wanfang database were retrieved to collect the randomized controlled trials（RCT） of benazepril（experiment group）vs. captopril（control group）in the treatment of primary hypertension. After information collection and quality evaluation,Meta-analysis was conducted by using Rev Man 5.0 software. RESULTS：Totally 7 RCTs involving 405 patients were included. The results of Meta-analysis showed that the level of systolic blood pressure（SBP）[MD=-2.06,95%CI（-3.75,-0.38）,P=0.02] and diastolic blood pressure（DBP）[MD=-3.10,95%CI（-5.19,-1.01）,P=0.004] in experiment group was significantly lower than control group;however,there were no significant differences between the efficacy rate of antihypertension[OR=1.63,95%CI（0.69,3.83）,P=0.26] and incidence of adverse drug reactions（ADR）[OR=0.81,95%CI（0.46,1.41）,P=0.45]in 2 groups. CONCLUSIONS：Benazepril can more effectively lower the blood pressure of patients with primary hypertension than captopril. Due to the limitation of methodology quality,it remains to be further verified by high-quality and large-sample RCT.
出处
《中国药房》
CAS
北大核心
2015年第18期2524-2526,共3页
China Pharmacy
